NCT01190813View on ClinicalTrials.gov

Levodopa for the Treatment of Residual Amblyopia

PHASE3CompletedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

January 31, 2014

Study Completion Date

April 30, 2014

Conditions
Amblyopia
Interventions
DRUG

Levodopa/Carbidopa

Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid

DRUG

Placebo

Oral placebo tid

OTHER

Patching

Two hours of daily patching

Trial Locations (1)

21287

Wilmer Eye Institute, Baltimore

Sponsors
All Listed Sponsors
collaborator

National Eye Institute (NEI)

NIH

lead

Jaeb Center for Health Research

OTHER